{"result": "(\"entity\"<|>EMA<|>ORGANIZATION<|>The European Medicines Agency (EMA) is responsible for the evaluation and supervision of medicinal products in the European Union.)\n##\n(\"entity\"<|>FEN/TPX<|>ORGANIZATION<|>FEN/TPX is a pharmaceutical combination that was studied for its effects on diabetes and obesity.)\n##\n(\"entity\"<|>BUPROPION<|>ORGANIZATION<|>Bupropion is a medication used for depression and smoking cessation, which affects neurotransmitters involved in appetite regulation.)\n##\n(\"entity\"<|>NALTREXONE<|>ORGANIZATION<|>Naltrexone is a medication that is used in combination with bupropion for weight management.)\n##\n(\"entity\"<|>ORLISTAT<|>ORGANIZATION<|>Orlistat is a weight loss medication that inhibits fat absorption in the intestines.)\n##\n(\"entity\"<|>MYSIMBA<|>ORGANIZATION<|>Mysimba is a brand name for the combination of bupropion and naltrexone, approved in Europe for weight management.)\n##\n(\"entity\"<|>CONTRA<|>ORGANIZATION<|>Contra is a brand name for the combination of bupropion and naltrexone, approved in the United States for weight management.)\n##\n(\"entity\"<|>POMC NEURONS<|>ORGANIZATION<|>POMC neurons are involved in the regulation of appetite and energy balance in the body.)\n##\n(\"entity\"<|>α-MSH<|>ORGANIZATION<|>Alpha-melanocyte-stimulating hormone (α-MSH) is a hormone that plays a role in appetite regulation.)\n##\n(\"entity\"<|>FDA<|>ORGANIZATION<|>The Food and Drug Administration (FDA) is a federal agency responsible for protecting public health by regulating food, drugs, and other products.)\n##\n(\"entity\"<|>DIABETES TYPE 2<|>EVENT<|>Diabetes type 2 is a chronic condition that affects the way the body processes blood sugar (glucose).)\n##\n(\"entity\"<|>OBESITY<|>EVENT<|>Obesity is a medical condition characterized by excessive body fat that increases the risk of health problems.)\n##\n(\"relationship\"<|>EMA<|>FEN/TPX<|>The EMA rejected the commercialization of FEN/TPX in Europe due to safety concerns<|>7)\n##\n(\"relationship\"<|>BUPROPION<|>NALTREXONE<|>Bupropion and naltrexone are combined for weight management<|>8)\n##\n(\"relationship\"<|>MYSIMBA<|>BUPROPION<|>Mysimba contains bupropion and is used for weight management<|>6)\n##\n(\"relationship\"<|>MYSIMBA<|>NALTREXONE<|>Mysimba contains naltrexone and is used for weight management<|>6)\n##\n(\"relationship\"<|>CONTRA<|>BUPROPION<|>Contra contains bupropion and is used for weight management<|>6)\n##\n(\"relationship\"<|>CONTRA<|>NALTREXONE<|>Contra contains naltrexone and is used for weight management<|>6)\n##\n(\"relationship\"<|>BUPROPION<|>POMC NEURONS<|>Bupropion stimulates POMC neurons which are involved in appetite regulation<|>8)\n##\n(\"relationship\"<|>POMC NEURONS<|>α-MSH<|>POMC neurons release α-MSH which regulates appetite<|>8)\n##\n(\"relationship\"<|>FDA<|>BUPROPION<|>The FDA regulates the approval and use of bupropion for medical purposes<|>9)\n##\n(\"relationship\"<|>FEN/TPX<|>DIABETES TYPE 2<|>FEN/TPX was studied for its effects on reducing the development of diabetes type 2<|>7)\n##\n(\"relationship\"<|>BUPROPION<|>OBESITY<|>Bupropion is used in the treatment of obesity<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: una diferencia\nmiento, parestesias, somnolencia, ansiedad, alteracio-              de tan solo 2,7 kg frente a placebo, fue suficiente para\nnes de la memoria, etc. que suelen disminuir con el                 reducir el desarrollo de diabetes tipo 2 en un 37,3% en\npaso del tiempo. La tasa de abandonos es solo del 31%               aquellos pacientes que tenían prediabetes15.\ncon las dosis más altas de FEN/TPX, una tasa alejada                  Contraindicaciones y precauciones: embarazo y lac-\ndel 45-50% de otros ensayos con fármacos de acción                  tancia, síndrome de malabsorción intestinal, colestasis\ncentral    (sibutramina,      lorcaserina,     naltrexona/bupro-    y nefrolitiasis por oxalatos. Hay que prestar especial\npión, etc.). También se ha podido verificar que la fre-             atención a la presencia de colelitiasis, hepatopatía, la\ncuencia de síntomas depresivos y necesidad de nuevos                posibilidad de malabsorción de vitaminas liposolubles\ntratamientos no es diferente del grupo placebo.                     y la interferencia en la absorción de levotiroxina, warfa-\n   En febrero de 2013, la EMA rechazó por segunda                   rina, antiepilépticos y ciclosporina, debiendo tomarse\nvez su comercialización en Europa aduciendo que la                  con un intervalo de al menos 4 horas con la toma de\nfentermina se asociaba a aumento de la frecuencia car-              orlistat10.\ndiaca y riesgo cardiovascular incierto a largo plazo,\nmientras que el TPM se asociaba a alteraciones de la                3.2.   Combinación de bupropión-naltrexona\natención, memoria y posible teratogenicidad (labio le-\nporino). Además, no se garantizaban los riesgos deri-                 Bupropión inhibe la recaptación de norepinefrina y\nvados del mal empleo que podría hacerse del fármaco                 dopamina, estando aprobada su comercialización para\ncon la libre dispensación de esta combinación para                  la depresión y el cese del hábito tabáquico. Esos neuro-\npacientes con obesidad.                                             transmisores están involucrados en la regulación del\n   Contraindicaciones y precauciones: gestación y lac-              apetito y mecanismos de recompensa, por lo que se\ntancia, glaucoma de ángulo estrecho, hipertiroidismo,               realizaron unos primeros estudios en pacientes obesos\ntoma concomitante de IMAO. Precaución en pacientes                  a corto plazo en los que se obtuvieron pérdidas de\ncon taquiarritmias, ansiedad y ataques de pánico, an-               peso entre el 7-10% en 24-48 semanas de tratamiento\ntecedentes de crisis comiciales, nefrolitiasis, acidosis            con 300-400 mg/día de bupropión16, pero con una\n---\n 136      BLOQUE: ALTERACIONES DE LA ENERGÍA\n\n\n\ntasa de abandonos del 43%. Sin embargo, la idea de                     tos     cardiovasculares        mayores        previstos     (muerte\nemplearlo en obesidad no progresó y se buscaron al-                    cardiovascular, ictus o infarto de miocardio no mortal),\nternativas como la combinación con otros fármacos.                     reveló que estos episodios se habían producido en el\n   La idea de combinar bupropión y naltrexona (Contra-                 2,3% de pacientes tratados con placebo y en el 2% de\nve® en EEUU y Mysimba® en Europa) se debe a que el                     pacientes del grupo de tratamiento activo (HR 0,88;\nbupropión es capaz de estimular las neuronas POMC                      ajustado al 99,7%; IC: 0,57-1,34)21. La FDA autoriza\nque, a su vez, liberan la hormona estimulante de mela-                 análisis intermedio (al 25% de seguimiento) para verifi-\nnocitos (α-MSH) para unirse a los receptores hipotalá-                 car que un fármaco no supera un riesgo inadmisible de\nmicos MC-4 (melanocortina-4), que tienen una potente                   1,8 veces superior al placebo (con un 95% de nivel de\nacción anorexígena. Las neuronas POMC simultánea-                      confianza). En el caso de BN se constató este supuesto,\nmente liberan una β-endorfina que actúa sobre los re-                  pero se desvelaron los resultados antes de finalizar el\nceptores opiodes-μ. La β-endorfina reduce la liberación                estudio previsto a 5 años. Así que no se obtendrán re-\nde α-MS\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}